Cabenuva Generic: When Will Generic Cabotegravir and Rilpivirine Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
Cabenuva Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? October 2040 About 14 years away Why then?
- Has the FDA approved a generic? Unknown No FDA Orange Book record under this name
- When does the brand’s protection end? Unknown Not in the FDA record we could read
- Can you buy a generic today? Not yet No company lists one for sale
Generic cabotegravir and rilpivirine is expected to be available in October 2040, about 14 years away. None is for sale yet.
Why October 2040?
A patent that protects the brand runs out. After that, approved generics can be sold. We rate it probable: more likely than not, but it can still move.
Will the generic cost less?
Usually, but no company is recorded as having applied to make one yet, and a single company usually brings only a modest drop. See the price pattern
What should I do now?
Keep taking Cabenuva as prescribed. When a generic arrives, your pharmacy may switch you to it automatically, and it may look different. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
Cabenuva by the Numbers
- Reason
- Patent expiresA patent that protects the brand runs out. After that, approved generics can be sold.
- How sure
- Probable More likely than not, but it can still move.
- Price competition
- None filed yet No filers on record
- Brand sales
- $2.1B a yearBlockbuster
- Medicare Part D spent $275.1M in 2025, for 8,278 people CMS Part D Spending by Drug
- Medicaid prescriptions 60.2K in the last four reported quarters, $365.4M CMS Medicaid drug utilization, to Q1 2026
Cabenuva’s Road to a Generic
The first generic of Cabenuva is expected in October 2040.
Why that month: a patent that protects the brand runs out. After that, approved generics can be sold.
The bar shows Cabenuva on the market on its own until the month we expect the first generic (the green band), a month and never a day. Its approval date and patents are not in the FDA Orange Book under this name, so the bar fades in from the left. The expected month comes from court records and company announcements.
Who Is Lined Up to Make Generic Cabotegravir and Rilpivirine
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
No company is recorded as having applied to the FDA to make a generic Cabenuva yet.
Approved by the FDA
We could not find Cabenuva’s own record in the FDA Orange Book under this name, so the approved generic makers are not shown.
For Sale in Pharmacies
Not yet. No company lists a generic cabotegravir and rilpivirine for sale with the FDA.
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
Cabenuva Price: What Pharmacies Pay and What Generics Usually Do
What a Generic Could Cost
How we estimate it. The national survey of what pharmacies pay (NADAC) has no recent price for Cabenuva, so we cannot show dollars. Here is the FDA’s finding of how far the price pharmacies pay usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017).
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
What Medicare and Medicaid Spend on Cabenuva
Big public spending is part of why generic makers line up for a medicine, and why its first generic matters beyond the pharmacy counter. Figures are before manufacturer rebates, which are confidential.
Medicare Part D Spending
What Medicare drug plans spent on Cabenuva, before manufacturer rebates.
- $76.8M
- January to March 2026, the latest CMS has posted
For 7,563 people, about $6,601 per prescription fill - $275.1M
- 2025, the whole year
For 8,278 people, about $6,524 per prescription fill
See the numbers
| Period | Spending | People | Per fill |
|---|---|---|---|
| January to March 2026 | $76,847,993 | 7,563 | $6,600.93 |
| 2025 | $275,082,269 | 8,278 | $6,524.41 |
Source: CMS Medicare Part D Spending by Drug, matched by the brand name Cabenuva only, so no generic is counted in it. What CMS says it is used for: This product is used to help control HIV infection. It contains 2 medications: cabotegravir and rilpivirine.
Medicaid Prescriptions by Quarter
60,221 prescriptions in the four quarters to Q1 2026, $365.4M paid.
See the numbers
| Quarter | Prescriptions | Medicaid paid |
|---|---|---|
| Q1 2026 | 14,705 | $91,882,695 |
| Q4 2025 | 16,126 | $97,581,736 |
| Q3 2025 | 15,436 | $93,664,062 |
| Q2 2025 | 13,954 | $82,266,021 |
| Q1 2025 | 13,568 | $78,875,824 |
Source: CMS Medicaid State Drug Utilization Data, over Cabenuva’s own package codes.
Cabenuva NDC Codes and Packages
Each Cabenuva package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.
| NDC | Product | Package | Company |
|---|---|---|---|
| 49702-0240-15 | kit | 1 KIT in 1 CARTON * 3 mL in 1 VIAL * 3 mL in 1 VIAL | ViiV Healthcare Company |
| 49702-0240-15 | kit | 1 KIT in 1 CARTON * 3 mL in 1 VIAL * 3 mL in 1 VIAL | ViiV Healthcare Company |
| 49702-0253-15 | kit | 1 KIT in 1 CARTON * 2 mL in 1 VIAL * 2 mL in 1 VIAL | ViiV Healthcare Company |
| 49702-0253-15 | kit | 1 KIT in 1 CARTON * 2 mL in 1 VIAL * 2 mL in 1 VIAL | ViiV Healthcare Company |
| 49702-0266-63 | kit | 1 KIT in 1 CARTON * 3 mL in 1 VIAL * 3 mL in 1 VIAL | ViiV Healthcare Company |
Source: the FDA NDC Directory, current listings only. Some codes belong to companies that repackage Cabenuva: it is the same medicine in a different package.
What a Generic Cabenuva Means for You
Nothing Changes Until It Is in Pharmacies
Until a generic is actually for sale, keep filling Cabenuva as usual. When one arrives, there is nothing you need to sign up for.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Until a generic is on US pharmacy shelves, be careful with websites that offer “generic Cabenuva”. The FDA warns that unlicensed online pharmacies sell counterfeit and unapproved medicines; its BeSafeRx page shows how to check a pharmacy.
Questions people ask about Cabenuva
Is there a generic for Cabenuva right now?
No. As of October 9, 2026 no generic cabotegravir and rilpivirine is listed for sale in the FDA NDC Directory.
When will Cabenuva go generic?
October 2040 is the expected month, and that is probable but not certain. A patent that protects the brand runs out. After that, approved generics can be sold.
Will generic cabotegravir and rilpivirine be the same as Cabenuva?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. No company is recorded as having applied to the FDA to make one yet, and a single company usually brings only a modest drop.
Changes to This Projection
- First generic expected October 2040 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- Jakafi XRRuxolitinib Phosphate2030 to 2031
- AphexdaMotixafortide AcetateSeptember 2030
- SivextroTedizolid PhosphateDecember 2030
- OlumiantBaricitinibJanuary to June 2032
- VoqueznaVonoprazan Fumarate2033 to 2034
- DylojectDiclofenac SodiumTBD no date yet
About Cabenuva
- Generic name cabotegravir and rilpivirine
- How it is taken Injection into a muscle
- Hard to copy Inhalers, injectables, patches and other hard-to-copy products. Fewer companies attempt them and dates slip more often.
- More drugs Brand-name drugs starting with C
- Have a question? A pharmacist answers, free. Ask about Cabenuva
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, FDA NDC Directory, CMS Medicare Part D Spending by Drug, Medicaid State Drug Utilization Data, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.